Présentation de l'entreprise
Ping An Biomedical Co., Ltd. operates as a provider of supply chain management services specifically tailored to the apparel industry across multiple international markets, including China, Hong Kong, Cambodia, and Europe. The company's operational scope encompasses a comprehensive range of services such as market trend analysis, product design and development, raw material sourcing, production oversight, and quality control. This entity functions within the Consumer Cyclical sector, specifically classified under the Textile Manufacturing industry, a classification that indicates its sensitivity to broader economic cycles and consumer spending patterns on discretionary goods. With a market capitalization of $18.31M and an annual revenue of $34.15M, the company represents a small-cap enterprise with a relatively modest operational footprint. The scale of Ping An Biomedical, evidenced by its limited market cap and the employment of only 7 individuals, suggests that the firm operates with a lean structure typical of specialized niche players rather than large-scale conglomerates, positioning it as a micro-cap stock with a total valuation significantly below major industry peers.
Santé financière
The financial performance of Ping An Biomedical Co., Ltd. is characterized by a revenue of $34.15M over the trailing twelve months, which contrasts sharply with a net income of $-12,829,206 and an EBITDA of $-14,695,886. The substantial gap between the reported revenue of $34.15M and the negative net income reveals a highly aggressive cost structure or significant non-operating expenses that consume nearly 38% of total sales before reaching the bottom line. Furthermore, the company generated a free cash flow of $-59,241,688, a figure that highlights a severe liquidity drain where cash outflows for operations and investments vastly exceed cash inflows, indicating a lack of financial flexibility to fund growth or weather downturns without external capital. The margin profile reflects this distress, with a gross margin of 2.8%, an operating margin of -69.6%, and a profit margin of -37.6%, all indicating that the core business operations are generating insufficient revenue to cover direct costs and that overhead expenses are disproportionately high relative to sales. On the balance sheet, the company holds $1.17M in cash against total debt of $10.47M, resulting in a debt-to-equity ratio of 23.14, which suggests a highly leveraged position where liabilities significantly outweigh equity. Despite the high debt load, the current ratio stands at 2.76, indicating that the company technically possesses sufficient current assets to cover its short-term liabilities, though the composition of these assets is likely heavily weighted toward receivables or inventory rather than liquid cash. Additionally, the return on equity is -67.4% and the return on assets is -14.7%, metrics that reveal that management effectiveness is currently negative, as the company is eroding shareholder value and utilizing its asset base inefficiently to generate profits.
Évaluation de la valorisation
Valuation multiples for Ping An Biomedical Co., Ltd. present significant challenges due to its profitability status, as the company does not have a trailing P/E ratio or a forward P/E ratio available, implying that traditional earnings-based valuation models are not applicable at this time. The absence of these ratios suggests that the market cannot value the stock based on current or expected earnings per share, which is typical for companies with negative earnings per share. Instead, the market capitalizes the company at a price-to-book ratio of 0.46, indicating that the stock is trading at a substantial discount to its book value, as the market price is less than half of the net asset value per share. Alternative valuation metrics such as the price-to-sales ratio of 0.54 and an EV/EBITDA of -0.88 further illustrate the lack of traditional valuation support, with the negative EV/EBITDA confirming that earnings are negative and the company is valued on a multiple of negative cash flow generation. The stock has exhibited extreme price volatility, trading between a 52-week high of $5.40 and a 52-week low of $0.12, meaning the current price sits in a range that reflects significant uncertainty regarding the company's future trajectory. The beta value is not available, which prevents a direct comparison of the stock's price volatility relative to the broader market, but the wide spread between the high and low prices suggests high idiosyncratic risk.
Growth & Income
The growth profile of Ping An Biomedical Co., Ltd. is currently contractionary, with revenue growth year-over-year at -62.0% and earnings growth year-over-year listed as N/A due to the negative earnings baseline. Since the company is reporting negative earnings, a traditional comparison of earnings growth versus revenue growth is not mathematically feasible, but the steep decline in revenue indicates a shrinking top line that exacerbates the existing cost structure issues. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests its minimal remaining earnings or utilizes cash reserves to sustain operations rather than distributing income to shareholders. This reinvestment strategy, combined with the absence of a dividend yield, results in an overall growth and income profile that is defined by contraction and a lack of income generation, making the stock unsuitable for investors seeking capital appreciation through earnings expansion or current income through dividends.